Rgene (Enzymes) Overview

  • Founded
  • 2014

  • Status
  • Private

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $491K

  • Investors
  • 1

Rgene (Enzymes) General Information


Developer of enzymes designed to use in molecular biology and genomics research. The company's products use protein engineering to improve enzyme properties for better in vitro application enabling enzyme reagents using protein engineering and data mining methods for molecular biotechnology.

Contact Information

Ownership Status
Privately Held (no backing)
Financing Status
Primary Industry
Primary Office
  • 953 Indiana Street
  • San Francisco, CA 94107
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rgene (Enzymes) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Grant 27-Mar-2015 $491K Completed Startup
To view Rgene (Enzymes)’s complete valuation and funding history, request access »

Rgene (Enzymes) Patents

Rgene (Enzymes) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3430154-A4 Hyper-thermostable lysine-mutant ssdna/rna ligases Active 14-Mar-2016 0000000000 0
US-20190062827-A1 Hyper-thermostable lysine-mutant ssdna/rna ligases Inactive 14-Mar-2016 0000000000
EP-3430154-B1 Hyper-thermostable lysine-mutant ssdna/rna ligases Active 14-Mar-2016 000000000 0
EP-3430154-A2 Hyper-thermostable lysine-mutant ssdna/rna ligases Active 14-Mar-2016 0000000000
AU-2017218431-A1 Multiple ligase compositions, systems, and methods Active 08-Feb-2016 C12N9/93
To view Rgene (Enzymes)’s complete patent history, request access »

Rgene (Enzymes) Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institute of General Medical Sciences Government 000 0000 000000 0
To view Rgene (Enzymes)’s complete investors history, request access »